Src

Hibarimicin C is a selective Src tyrosine kinase inhibitor that modulates cellular signaling pathways involved in various cancers. It exhibits significant specificity by inhibiting Src activity while leaving protein kinases A and C unaffected. In addition to its role in cancer research, Hibarimicin C displays moderate antibacterial activity against Gram-positive bacteria, with a minimum inhibitory concentration (MIC) ranging from 0.8 to 12.56 μg/mL. This compound is pertinent for studies in oncology and microbiology.

Hibarimicin B is a selective Src tyrosine kinase inhibitor that effectively disrupts Src activity while not interfering with protein kinase A or C. This compound demonstrates moderate antibacterial activity against Gram-positive bacteria, with a minimum inhibitory concentration (MIC) range of 0.8-12.56 μg/mL. Hibarimicin B is utilized in research applications focused on cancer cell signaling pathways and microbial resistance mechanisms.

Hibarimicin D is a selective inhibitor of the Src tyrosine kinase, effectively disrupting its enzymatic activity while sparing protein kinases A and C. In addition to its role as a Src inhibitor, Hibarimicin D exhibits moderate antibacterial properties against Gram-positive bacteria, with a minimum inhibitory concentration (MIC) ranging from 0.8 to 12.56 μg/mL. This compound offers valuable applications in research focused on cancer signaling pathways and antibacterial studies.

JP-153 is a Src-FAK-Paxillin signaling inhibitor that specifically targets the Src-dependent phosphorylation of paxillin at tyrosine 118, leading to downstream inhibition of Akt activation at serine 473. This compound effectively reduces VEGF-induced migration and proliferation in retinal endothelial cells, making it a valuable tool for studying neovascular eye diseases. Researchers can utilize JP-153 to explore the molecular mechanisms underlying angiogenesis and potential therapeutic interventions.

(E/Z)-MCB-613 is a pan-Steroid Receptor Coactivator (SRC) stimulator that enhances SRC activity in cancer cells. This leads to the overstimulation of reactive oxygen species (ROS) production, resulting in cell stress and apoptosis through a mechanism known as paraptosis. (E/Z)-MCB-613 serves as a cytotoxic agent with significant implications for cancer research, particularly in studies focusing on targeted cancer therapies and mechanisms of cell death.

Canine Secretin is an endocrine hormone that primarily targets the Src kinase pathway. It stimulates the secretion of bicarbonate-rich pancreatic fluids and regulates gastric chief cell function, as well as paracellular permeability in canine gastric monolayers. This reagent is valuable for research applications involving gastrointestinal physiology and pancreatic function in canines.

AZ12672857 is a potent inhibitor of EphB4 and Src kinases, demonstrating an IC50 of 1.3 nM for EphB4. This compound significantly inhibits the proliferation of c-Src transfected 3T3 cells with an IC50 of 2 nM and autophosphorylation of EphB4 in CHO-K1 cells with an IC50 of 9 nM. AZ12672857 can be utilized in studies investigating signaling pathways related to cancer and cell growth regulation.

ND1-YL2 is a PROTAC that selectively targets and degrades SRC-1 through the N-degron pathway. This compound has demonstrated significant inhibition of cancer cell invasion and migration both in vitro and in vivo. ND1-YL2 serves as a valuable tool in cancer research, providing insights into the role of SRC-1 in tumor progression and metastasis.

SI-2 hydrochloride is a potent inhibitor of SRC-3, a transcription co-regulator involved in various signaling pathways. This compound displays favorable pharmacokinetic properties and reduced toxicity, making it suitable for in vivo studies. SI-2 hydrochloride is valuable for research related to cancer biology, endocrine signaling, and other conditions where SRC-3 plays a critical role.

(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.

TG 100948 is a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase Src. This compound demonstrates significant biological activity by reducing retinal edema and retinal thickening, as well as eliminating bullous edema cysts in rat models of ischemic retinal vein occlusion. TG 100948 is valuable for research into the pathophysiology and potential treatments of ischemic retinal vein occlusion.